TLDR
- HSBC downgraded Eli Lilly (LLY) from Hold to Reduce, cutting its price target from $1,070 to $850
- Analyst Rajesh Kumar says LLY is “priced to perfection” after a 20% gain over the past 12 months
- HSBC slashed its obesity drug market TAM forecast to $80–120bn by 2032, down from consensus of $150bn+
- Concerns raised over orforglipron launch expectations, pricing pressure, and heavy reliance on the cash-pay channel
- LLY fell 1.6% to $972.51 following the downgrade; rival Novo Nordisk (NVO) is down 52% over the same 12-month period
Eli Lilly has had a strong run. Up 20% over the past year while rival Novo Nordisk has lost more than half its value, LLY looked like the clear winner in the weight-loss drug race. But HSBC thinks the market may have gotten ahead of itself.
On Tuesday, HSBC analyst Rajesh Kumar downgraded Lilly to Reduce from Hold and cut his price target to $850 from $1,070. The stock dropped 1.6% to $972.51 on the news.
Kumar’s core argument is simple: the stock is “priced to perfection,” leaving little room for error.
The downgrade rests on three main concerns. The first is the size of the obesity drug market itself. HSBC now estimates a total addressable market of $80–120 billion by 2032. That’s well below the $150 billion-plus figure many on Wall Street have been working with.
That gap matters. A smaller market ceiling means less room for the revenue growth already baked into Lilly’s valuation.
Orforglipron Expectations Look Too High
The second concern is Lilly’s upcoming oral weight-loss pill, orforglipron. The drug is expected to launch later this year and has generated real excitement — consensus 2026 sales forecasts are running between $1.1 billion and $1.3 billion.
HSBC thinks that’s too high. Kumar wrote that “the compliance and persistence of these drugs might disappoint,” and noted those estimates appear anchored to a $1.5 billion inventory build Lilly has already made ahead of the launch.
Building inventory is a sign of confidence. But it also raises the stakes if the drug underperforms.
Pricing Pressure Is Building
The third concern is pricing. Lilly faces price cuts in 2026 from the broader competitive environment, and HSBC flagged “rising working capital intensity” and deteriorating “rebate dynamics” as warning signs.
Kumar also pointed to the gap between Lilly’s and Novo Nordisk’s guidance — something he says has puzzled most investors. His read is that Lilly’s outperformance has been driven by the cash-pay channel, where customers pay out of pocket rather than through insurance.
That channel is more sensitive to economic conditions and, HSBC warned, could be disrupted by AI-linked changes to the labour market.
HSBC still sees the broader healthcare sector as well-positioned for the next quarter. But within that, Kumar views Lilly’s risk-reward as unfavourable at current levels.
LLY was trading at $972.51 at the time of the downgrade, more than $120 above HSBC’s new $850 price target.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
